Previous studies demonstrated that alternative splicing of HMGCR was associated with individual variability in statin efficacy, [20, 21] and the variant HMGCR gene was not only associated with LDL-C concentrations [9] but also raised CHD risk, particularly in patients with severe coronary artery disease [11]. This evidence concerns the gene HMGCR and coronary artery disorder.